Using a new tool to support decisions for patients with ischemic heart disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the PM-Heart algorithm, a software designed to predict survival prognosis for patients hospitalized with ischemic heart disease after undergoing coronary arteriography. The algorithm serves as a clinical decision support system, enhancing physicians' therapeutic considerations without dictating specific actions. The study aims to determine if using this algorithm improves patient outcomes and reduces the risk of re-hospitalization compared to standard treatment without the algorithm's input.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Hospitalized patients in one of the involved departments of cardiology (see below) with;
* Ischemic heart disease; the clinical presentation may be stable, worsening/unstable angina, non-ST-elevation myocardial infarction or ST-elevation myocardial infarction, and with - Significant coronary artery lesions or diffuse coronary artery disease on invasive coronary angiography during the admission

Exclusion Criteria:

* \<18 years of age
* Living outside Denmark

Where it's running

• Department of Cardiology, The Heart Centre, Rigshospitalet Copenhagen University Hospital.
  Copenhagen Ø, Denmark Recruiting

Study contacts

• Study coordinator: Henning Bundgaard, Professor
• Email: henning.bundgaard@regionh.dk
• Phone: +4535450512

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Outpatient Cardiac Telerehabilitation for Ischemic Heart Disease

  This study tests whether an outpatient cardiac telerehabilitation program can be as safe and effective as conventional rehab for people with ischemic heart disease.

  Recruiting Lithuanian University of Health Sciences · Kulautuva · NCT07927829

• See if stopping long-term aspirin is as good as continuing it in older adults with stable ischemic heart disease

  In adults 65 and older with stable ischemic heart disease, this trial tests whether stopping daily low-dose aspirin is not worse than continuing it.

  Recruiting at 2 sites Phase 4 Odense University Hospital · Copenhagen and 1 other locations · NCT07795398

• QFR-guided virtual stenting to optimize PCI before the procedure

  We’re testing whether using QFR-based virtual stenting before PCI can improve heart-procedure outcomes compared with standard angiography planning in adults with coronary artery disease.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07635407

• LONG NAGOMI PMCF: follow-up of the Ultimaster Nagomi stent in long coronary artery lesions

  This project tests the Ultimaster Nagomi drug-eluting stent in adults undergoing PCI for long coronary lesions to collect real-world safety and effectiveness data.

  Recruiting at 10 sites Fundación EPIC · Cabueñes and 9 other locations · NCT07399002

• Endocardial delivery of stem-cell derived heart cells to help severe heart failure

  This study tests endocardial delivery of HS-001 cell sheets made from iPSC-derived cardiomyocytes in adults with severe heart failure and reduced ejection fraction to see if it is safe and may improve heart function over 26 weeks.

  Recruiting at 5 sites Phase 1/2 Heartseed Inc. · Tsukuba, Ibaraki and 4 other locations · NCT07347197

• Deep learning to analyze and track echocardiograms

  This project will test AI tools that help clinicians read echocardiograms and flag adults who may have genetic cardiomyopathy, ischemic heart disease, or cardiac amyloidosis to see if interpretation improves and diagnoses happen faster.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07308704

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.